The first global systematic review and meta-analysis of hepatitis B care has found critical patient losses at every step of ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

The first series created by writer and director Eduardo Casanova, of which a clip is now available, tells the story of ...